TY - JOUR T1 - Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience JO - Oncology Reports PY - 2008/01/01 AU - Ansari ED - DO - DOI: 10.3892/or_00000088 PB - Spandidos Publications VL - 20 IS - 4 Y2 - 2025/07/17 ER -